OraSure Technologies, Inc. (OSUR) Expected to Earn Q2 2018 Earnings of $0.04 Per Share

OraSure Technologies, Inc. (NASDAQ:OSUR) – Jefferies Group decreased their Q2 2018 earnings per share estimates for OraSure Technologies in a report released on Tuesday. Jefferies Group analyst B. Couillard now forecasts that the medical instruments supplier will post earnings of $0.04 per share for the quarter, down from their prior forecast of $0.09. Jefferies Group currently has a “Hold” rating on the stock. Jefferies Group also issued estimates for OraSure Technologies’ FY2018 earnings at $0.27 EPS.

Several other research firms have also issued reports on OSUR. Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Tuesday. Canaccord Genuity reiterated a “buy” rating and set a $24.00 target price on shares of OraSure Technologies in a report on Friday, February 2nd. BidaskClub upgraded shares of OraSure Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Finally, ValuEngine lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. OraSure Technologies presently has an average rating of “Buy” and a consensus target price of $22.25.

Shares of OraSure Technologies (OSUR) opened at $17.28 on Wednesday. The stock has a market capitalization of $1,058.92, a PE ratio of 33.88, a P/E/G ratio of 4.46 and a beta of 1.43. OraSure Technologies has a 12 month low of $10.28 and a 12 month high of $23.01.

OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, February 7th. The medical instruments supplier reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. OraSure Technologies had a return on equity of 13.09% and a net margin of 18.52%. The business had revenue of $52.00 million for the quarter, compared to the consensus estimate of $50.20 million. During the same quarter last year, the business posted $0.13 earnings per share. The company’s revenue for the quarter was up 46.5% on a year-over-year basis.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. raised its holdings in OraSure Technologies by 2.7% in the 4th quarter. BlackRock Inc. now owns 7,729,515 shares of the medical instruments supplier’s stock worth $145,778,000 after acquiring an additional 201,251 shares during the last quarter. Vanguard Group Inc. grew its position in OraSure Technologies by 19.8% in the 2nd quarter. Vanguard Group Inc. now owns 5,352,832 shares of the medical instruments supplier’s stock worth $92,390,000 after purchasing an additional 886,333 shares during the period. Dimensional Fund Advisors LP grew its position in OraSure Technologies by 5.8% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,057,690 shares of the medical instruments supplier’s stock worth $52,777,000 after purchasing an additional 167,642 shares during the period. State Street Corp grew its position in OraSure Technologies by 6.9% in the 2nd quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock worth $28,305,000 after purchasing an additional 106,326 shares during the period. Finally, Fuller & Thaler Asset Management Inc. grew its position in OraSure Technologies by 175.6% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 898,397 shares of the medical instruments supplier’s stock worth $20,214,000 after purchasing an additional 572,397 shares during the period. Institutional investors own 91.62% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/orasure-technologies-inc-osur-expected-to-earn-q2-2018-earnings-of-0-04-per-share.html.

OraSure Technologies Company Profile

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply